Research institute

The Song of the Earth: Artistic Documentary for a Better China Exhibition by CAA held in Beijing

Retrieved on: 
星期三, 四月 17, 2024
Local government, Digital technology, Education, Agriculture, Exhibition, School, Research, Biophysical environment, CAA, Tourism, Culture, Ministry, Environment, Song, Multimedia, Natural Resources, Civilization, Research institute, Government, Philosophy, China Millennium Monument

BEIJING, April 16, 2024 /PRNewswire/ -- The Song of the Earth: Artistic Documentary for a Better China exhibition opened on March 20 at China Millennium Monument's Beijing World Art Museum.

Key Points: 
  • BEIJING, April 16, 2024 /PRNewswire/ -- The Song of the Earth: Artistic Documentary for a Better China exhibition opened on March 20 at China Millennium Monument's Beijing World Art Museum.
  • This exhibition presents typical stories of two complementary threads to interpret the concept of a "Better China".
  • The Song of the Earth: Artistic Documentary for a Better China exhibition takes "experiencing China's geography" as its gist.
  • While appreciating society-wide innovative efforts to create a Better China, they can embark on a magnificent tour of a Better China.

New Findings in JNCCN Illustrate Pathway for Screening High-Risk Individuals for Pancreatic Cancer in PRECEDE Study

Retrieved on: 
星期二, 四月 16, 2024
University, Clinical trial, NCCN, Pancreas, McGill University Health Centre, Risk, Pancreatic cancer, Breast, Prevalence, Cancer, National Comprehensive Cancer Network, Rosalind, Survival, Survival rate, Cyst, Doctor of Philosophy, Huntsman Cancer Institute, Research, Moores Cancer Center, Consortium, Disease, Incidence, Patient, Pancreatic Cancer Action Network, Diagnosis, Research institute, PGV, Dana–Farber Cancer Institute, Morávek, UC, McGill University, Pharmaceutical industry

PLYMOUTH MEETING, Pa., April 16, 2024 /PRNewswire/ -- New research in the April 2024 issue of JNCCN—Journal of the National Comprehensive Cancer Network showcases the feasibility of improving early detection and prevention for pancreatic cancer. Global incidences of pancreatic cancer have risen dramatically in recent years, but the overall survival rate is currently only 12%. When pancreatic neoplasms are detected early enough for treatment with surgical resection, the survival rate climbs to better than 80%, but unfortunately the vast majority of patients are diagnosed with advanced-stage disease. The Pancreatic Cancer Early Detection (PRECEDE) Consortium is a global effort to increase screening capacity for this disease. Of 1,759 participants sorted into the highest-risk cohort, nearly 80% completed baseline imaging through PRECEDE.

Key Points: 
  • Global incidences of pancreatic cancer have risen dramatically in recent years, but the overall survival rate is currently only 12%.
  • The Pancreatic Cancer Early Detection (PRECEDE) Consortium is a global effort to increase screening capacity for this disease.
  • "I look forward to further research... to improve access to pancreatic cancer screening for high-risk individuals."
  • "Longer follow-up time is needed to determine if familial pancreatic cancer signifies a higher risk for developing pancreatic cancer compared to pathogenic germline variant (PGV) status in a pancreatic cancer predisposition gene."

LEXUS PRESENTS "TIME" AT THE 2024 MILAN DESIGN WEEK

Retrieved on: 
星期一, 四月 15, 2024
Midnight, SIHH, System, Product design, University of Tokyo, Death, New National Theatre Tokyo, Postgraduate education, Life, Singing, Tree, Horizon, Music award, Android, OPV, Exhibition, COS, Software, EV, Research institute, Absolute music, Aerospace engineering, Design, Tangent, Milan Furniture Fair, Bev, Royal college, Power station, Solar energy, Transport, Carbon, Engineering, Light, Japanese Movie Critics Awards, Organic solar cell, Swarovski, University, Glass, BEV, Liberal arts college, History, Calligraphy Greenway, Superstudio, Advanced Art, Sound, Renewable energy

MILAN, April 15, 2024 /PRNewswire/ -- Lexus has unveiled its installation Time at the world's largest design event, Milan Design Week, in Milan, Italy. Located in Art Point and Art Garden at the Superstudio Più in the Tortona design district, a hub for global creative convergence, the exhibit is open until April 21, 2024.

Key Points: 
  • MILAN, April 15, 2024 /PRNewswire/ -- Lexus has unveiled its installation Time at the world's largest design event, Milan Design Week, in Milan, Italy.
  • It also expresses Lexus' resolve to redefine luxury in synergy with carbon neutrality, exploring how energy and software can advance mobility innovation.
  • At Art Point, Hideki Yoshimoto/Tangent presents Beyond the Horizon, expressing a world of next-generation mobility that evolves infinitely through software.
  • Furthermore, she was appointed as an ambassador for the Dutch Design Week in 2022, enhancing her commitment to solar energy.

PolyU researchers introduce biomineralisation as sustainable strategy against microbial corrosion in marine concrete

Retrieved on: 
星期三, 四月 10, 2024
Biomineralization, MIC, Hong Kong Polytechnic University, Polytechnic, Bacteria, Sewage, Hydrogen sulfide, Environmental Science & Technology, Research, Carbon footprint, Carbon, Corrosion, Ground substance, Environment, Biofilm, Faculty, SRB, Construction, Environmental science, Research institute, Urban, Lumber

In response to the need for an effective solution to combat marine corrosion in concrete, The Hong Kong Polytechnic University (PolyU) researchers have developed a biomineralisation approach to protect marine concrete from MIC.

Key Points: 
  • In response to the need for an effective solution to combat marine corrosion in concrete, The Hong Kong Polytechnic University (PolyU) researchers have developed a biomineralisation approach to protect marine concrete from MIC.
  • This biomineralisation strategy has strong potential for applications in corrosive environments, such as in marine and sewage settings, and water-cooling utilities, where concrete corrosion is induced by corrosive microorganisms.
  • A paper reporting the research, " Biomineralisation to prevent microbially induced corrosion on concrete for sustainable marine infrastructure ", has been published in Environmental Science & Technology.
  • The results contribute to the development of new techniques for inhibiting corrosion to achieve sustainable marine concrete structures.

PolyU researchers introduce biomineralisation as sustainable strategy against microbial corrosion in marine concrete

Retrieved on: 
星期三, 四月 10, 2024
Biomineralization, MIC, Hong Kong Polytechnic University, Polytechnic, Bacteria, Sewage, Hydrogen sulfide, Environmental Science & Technology, Research, Carbon footprint, Carbon, Corrosion, Ground substance, Environment, Biofilm, Faculty, SRB, Construction, Environmental science, Research institute, Urban, Lumber

In response to the need for an effective solution to combat marine corrosion in concrete, The Hong Kong Polytechnic University (PolyU) researchers have developed a biomineralisation approach to protect marine concrete from MIC.

Key Points: 
  • In response to the need for an effective solution to combat marine corrosion in concrete, The Hong Kong Polytechnic University (PolyU) researchers have developed a biomineralisation approach to protect marine concrete from MIC.
  • This biomineralisation strategy has strong potential for applications in corrosive environments, such as in marine and sewage settings, and water-cooling utilities, where concrete corrosion is induced by corrosive microorganisms.
  • A paper reporting the research, " Biomineralisation to prevent microbially induced corrosion on concrete for sustainable marine infrastructure ", has been published in Environmental Science & Technology.
  • The results contribute to the development of new techniques for inhibiting corrosion to achieve sustainable marine concrete structures.

QIAGEN strengthens its portfolio for cancer research, showcasing latest product launches at AACR Annual Meeting 2024

Retrieved on: 
星期三, 四月 3, 2024
EGFR, Gene, Nested polymerase chain reaction, Professor, Cancer Institute, Circulating free DNA, Neoplasm, TCR, Research institute, QGEN, Research, PCR, Central business district, NGS, DNA, BRAF, Diagnosis, WIA, Cancer, Immune system, Liquid biopsy, UMI, Mutation, Genetics, Human genetics, Senior, AACR, Medical school, QIAGEN, Poster, Environment, IVD, Urine

Two Exhibitor Spotlight Theater sessions and several poster presentations will highlight additional advances from QIAGEN in this field.

Key Points: 
  • Two Exhibitor Spotlight Theater sessions and several poster presentations will highlight additional advances from QIAGEN in this field.
  • EGFR and BRAF are genes essential for normal cell growth and function, but mutations in these genes can result in cancer development.
  • To advance research on how the immune system interacts with cancer, QIAGEN has introduced the QIAseq Targeted RNA-seq Panel for T-cell receptors.
  • Learn more about QIAGEN’s offering at the AACR Annual Meeting 2024, (booth #922 in the San Diego Convention Center) and poster presentations highlighting new solutions in digital PCR, NGS and preanalytical workflows at https://www.qiagen.com/applications/cancer-research/aacr-2024-annual-mee... .

Allterum Therapeutics receives $12 million product development grant from CPRIT to advance anti-CD127 therapeutic antibody into clinic

Retrieved on: 
星期一, 四月 8, 2024
NCI, Acute lymphoblastic leukemia, CLL, Immunotherapy, AML, TTC, Lung, Patient, ALL, NeXT, National Cancer Institute, Breast, Cancer, Pediatrics, Doctor of Philosophy, IND, GMP, Clinical trial, Investigational New Drug, Therapy, Immune system, Prognosis, Research institute, Cancer prevention, FDA, Lymphoma, CD127, Pharmaceutical industry

HOUSTON, April 8, 2024 /PRNewswire-PRWeb/ -- Allterum Therapeutics, Inc. has been awarded a $12 million product development grant from the Cancer Prevention and Research Institute of Texas (CPRIT), which will support the clinical evaluation of Allterum's lead candidate, 4A10, a monoclonal antibody targeting CD127. CD127 is a receptor that is expressed in major subsets of multiple cancers including hematological cancers (ALL, AML, CLL, and lymphoma) and solid tumors (lung, breast, colorectal, H&N, esophageal cancers).

Key Points: 
  • Allterum Therapeutics, Inc. has been awarded a $12 million product development grant from the Cancer Prevention and Research Institute of Texas (CPRIT).
  • HOUSTON, April 8, 2024 /PRNewswire-PRWeb/ -- Allterum Therapeutics, Inc. has been awarded a $12 million product development grant from the Cancer Prevention and Research Institute of Texas (CPRIT), which will support the clinical evaluation of Allterum's lead candidate, 4A10, a monoclonal antibody targeting CD127.
  • An addition to the $12M Product Development Award, Allterum received a $2.9M CPRIT seed award in 2020, which supported early-stage development work for the 4A10 antibody and laid the foundation for the current grant.
  • "We are pleased to provide Allterum with this TTC product development award to advance their promising anti-cancer drug into clinic," said Dr. Kenneth Smith, CPRIT's Chief Product Development Officer.

Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic

Retrieved on: 
星期一, 三月 25, 2024
Diagnosis, Certification, LM, Plus Therapeutics, NSCLC, CSF, Partnership, Central nervous system, Patient, CNS, Breast, PSTV, Lung cancer, Clinical trial, Therapy, Cancer, Rhenium, CLIA, Research institute, Cancer prevention, Feinberg School of Medicine, Associate professor

AUSTIN, Texas, March 25, 2024 (GLOBE NEWSWIRE) --  Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced it has successfully completed key validation testing and implementation of its tumor cell enumeration assay, known as CSF-01, to be used initially as an exploratory endpoint in its ReSPECT-LM clinical trials.

Key Points: 
  • “In mid-2023, the Company licensed CSF-01, as well as a broader CSF diagnostic testing portfolio due to high conviction that routine implementation will substantially improve diagnosis and clinical management of LM,” said Marc H. Hedrick, M.D., President & CEO of Plus Therapeutics.
  • While validated for use in Plus’ clinical development programs, full Clinical Laboratory Improvement Amendments (CLIA) certification is not anticipated until 2025.
  • The ReSPECT-LM trial, including support for CSF-01 testing, is currently receiving grant funding from the Cancer Prevention and Research Institute of Texas (CPRIT).
  • If the FORSEE data is positive, we intend to work toward increasing commercial reimbursement for the CLIA-certified test and explore partnerships to maximize diagnostic utilization for the broader CNS cancer space.

Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Recent Business Highlights

Retrieved on: 
星期四, 三月 21, 2024
Administration, Head, TIL, Colorectal cancer, Immunotherapy, HNSCC, Takeda Oncology, Selection, Patient, G&A, Melanoma, TILS, Investment, CRC, Breast cancer, SITC, Research and development, Research institute, Turnstone, Uveal melanoma

SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided recent business highlights.

Key Points: 
  • “2023 marked a transformative year for Turnstone Biologics in which we transitioned into a publicly traded company and continued to advance our pipeline through clinical development.
  • Recently, Turnstone expanded their trials to evaluate additional solid tumor types in addition to the existing indications of breast cancer and uveal melanoma.
  • Preclinical Data Presentations at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting Support Ongoing Clinical and Preclinical Efforts.
  • Cash, Cash Equivalents and Short-Term Investments: As of December 31, 2023, cash, cash equivalents and short-term investments were $94.8 million.

Arrcus to Demonstrate Secure 5G Networking on NVIDIA BlueField-3 DPUs

Retrieved on: 
星期四, 三月 14, 2024
5G, Software, Networks, Internet, Artificial Intelligence, Data Management, Technology, Carriers and Services, PDT, CIO, GTC, DPU, MUP, Transport, Nvidia BlueField, Market development, Senior, SoftBank Group, Inception, NOS, ARCOS-1, Advanced technology, Telecom, Research institute, Central processing unit, IPsec, CPU, Cryptocurrency

Implemented with SRv6 MUP technology on the NVIDIA BlueField-3 DPU, the proof of concept seeks to deliver data through a secure 5G network slice.

Key Points: 
  • Implemented with SRv6 MUP technology on the NVIDIA BlueField-3 DPU, the proof of concept seeks to deliver data through a secure 5G network slice.
  • "We are thrilled to work with NVIDIA and SoftBank to accelerate the deployment of secure 5G network slices," said Shekar Ayyar, Chairman, and CEO of Arrcus.
  • "NVIDIA BlueField DPUs are purpose-built to offload, accelerate, and isolate data center workloads, making them ideal for secure and power efficient 5G network slices,” said Ronnie Vasishta, Senior Vice President of Telecom at NVIDIA.
  • "The integration of BlueField DPUs with Arrcus’ SRv6 technology will help make the deployment of a secure 5G network possible."